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Abstract 
Background Delivery of small interfering RNA (siRNA) to tumours remains a major obstacle 
for the development of RNA interference (RNAi)-based therapeutics. Following the promising 
pre-clinical and clinical results with the oncolytic herpes simplex virus (HSV) OncoVEXGM-CSF, 
we aimed to express RNAi triggers from oncolytic HSV, which although has the potential to 
improve treatment by silencing tumour-related genes, was not considered possible due to 
the highly oncolytic properties of HSV. 
 
Methods To evaluate RNAi-mediated silencing from an oncolytic HSV backbone, we 
developed novel replicating HSV vectors expressing short-hairpin RNA (shRNA) or artificial 
microRNA (miRNA) against the reporter genes green fluorescent protein (eGFP) and β-
galactosidase (lacZ). These vectors were tested in non-tumour cell lines in vitro and tumour 
cells that are moderately susceptible to HSV infection both in vitro and in mice xenografts in 
vivo. Silencing was assessed at the protein level by fluorescent microscopy, x-gal staining, 
enzyme activity assay, and western blotting.  
 
Results Our results demonstrate that it is possible to express shRNA and artificial miRNA 
from an oncolytic HSV backbone, which had not been previously investigated. Furthermore, 
oncolytic HSV-mediated delivery of RNAi triggers resulted in effective and specific silencing 
of targeted genes in tumour cells in vitro and tumours in vivo, with the viruses expressing 
artificial miRNA being comprehensibly more effective. 
 
Conclusions This preliminary data provide the first demonstration of oncolytic HSV-
mediated expression of shRNA or artificial miRNA and silencing of targeted genes in tumour 
cells in vitro and in vivo. The vectors developed in this study are being adapted to silence 
tumour-related genes in an ongoing study that aims to improve the effectiveness of oncolytic 
HSV treatment in tumours that are moderately susceptible to HSV infection and thus, 
potentially improve response rates seen in human clinical trials.  
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Background 
RNA interference (RNAi) has emerged not only as a powerful tool in functional genomics 
and the validation of novel gene targets in drug discovery, but also as a potential therapeutic 
strategy for diverse diseases, including cancer [1]. RNAi is a post-transcriptional gene 
silencing mechanism mediated by small double-stranded RNA (dsRNA) molecules, including 
small interfering RNAs (siRNAs) and microRNAs (miRNAs) [2-6]. In mammalian cells, RNAi 
can be induced by synthetic siRNAs introduced directly into the cell or by plasmid and viral 
vectors that express short-hairpin RNA (shRNA) or artificial miRNAs, which have been 
termed the new generation RNAi triggers [7-9]. 
 
Although a variety of strategies, such as chemical modifications, liposomes, nanoparticles, 
and antibodies or cell-surface receptors, have been employed to increase siRNA stability 
and delivery to specific cell types [10], in vivo delivery of siRNAs remains a major obstacle 
for the development of RNAi-based cancer therapeutics. As a more efficient alternative, 
replication-defective viral vectors have been developed to silence genes in tumours. A 
retroviral vector has demonstrated silencing of HER-2/neu [11]. Lentiviral vectors have been 
employed to silence a number of tumour-associated genes, including Tiam1, resulting in 
suppression of cancer cell growth in vitro and in vivo [12]. Similar inhibition of tumour cell 
growth has been achieved by adenoviruses expressing shRNA against ASH1, p28GANK, 
Skp-2 and Hec1 [13-15]. Furthermore, herpes simplex virus (HSV) amplicon vectors have 
been shown to silence genes in tumour cells both in vitro and in vivo [16,17]. 
 
Replicating viruses engineered to exhibit selective tumour cytotoxicity have a significant 
advantage over non-replicating viruses. A number of oncolytic viruses are currently under 
clinical development for cancer therapy. Thus, there is considerable interest in expressing 
shRNA from these viruses to improve their tumour killing properties. Oncolytic adenovirus 
expressing shRNA against the firefly luciferase transgene achieved 30% silencing in a 
number of tumour cell lines [18]. More recently, replication-competent adenoviruses 
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expressing shRNA against vascular endothelial growth factor (VEGF) and Interleukin-8 (IL-8) 
have been shown to affect angiogenesis and inhibit tumour growth [19,20]. 
 
OncoVEX is a second-generation oncolytic HSV-1 with deletion in ICP34.5 to provide tumour 
selective replication [21,22] and deletion of ICP47 resulting in the expression of the US11 
gene as an immediate-early (IE) rather than a late (L) gene to further increase tumour 
replication [23]. Infection of cells with wild type HSV reduces antigen expression on the cell 
surface through the expression of ICP47, which inhibits the transporters associated with 
antigen presentation (TAP) [24,25]. Therefore, deletion of ICP47 would be expected to 
increase the anti-tumour immune response in the presence of HSV [26,27]. This oncolytic 
HSV-1 backbone has demonstrated improved tumour shrinkage properties compared to 
previously developed oncolytic viruses and has been used to successfully express a range 
of therapeutic genes in pre-clinical testing, including granulocyte macrophage colony-
stimulating factor (GM-CSF), retroviral glycoprotein, pro-drug activating system, and Tumor 
Necrosis Factor-Alpha (TNFα) [28-30]. OncoVEXGM-CSF has been further tested in Phase I 
and Phase II clinical trials by direct injection into a number of tumour types with promising 
results [31], and has entered Phase III clinical studies in melanoma. While enhanced activity 
has been observed when therapeutic genes have been inserted into oncolytic HSV-1 
genomes, expression of shRNA had not been previously investigated.    
 
Following the promising pre-clinical and clinical results with OncoVEX, the current study 
aimed to identify whether it was possible to express shRNA and artificial miRNA from an 
oncolytic HSV backbone. To this end, we developed viruses expressing shRNA or pre-
miRNA against β-galactosidase (lacZ) or enhanced green fluorescent protein (eGFP) and 
evaluated the potential of these vectors both in vitro and in vivo. We demonstrate, for the 
first time, that shRNA and artificial miRNA can be expressed from an oncolytic HSV virus 
and results in effective silencing of reporter genes in vitro in non-tumour cells that are highly 
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susceptible and tumour cells that are moderately susceptible to HSV infection and in vivo in 
tumours that are not cured by oncolytic virus treatment alone. Ultimately, by down regulating 
the levels of proteins secreted by tumour cells, which aid their growth or promote local 
immune suppression, we may further improve tumour cell killing by oncolytic HSV in tumours 
that are moderately susceptible to HSV oncolysis. In the clinical situation, this is expected to 
increase the response rates seen. For example, in melanoma, response rates were 
approximately 30% in a phase II clinical trial and therefore, increasing this rate of response 
using RNAi, or other approaches, would be clearly clinically beneficial. 
 
Methods 
 
Cell lines 
All cell lines were obtained from either ATCC or ECACC or produced by the authors and 
were grown at 370C in recommended media under a humidified atmosphere of 5% CO2. The 
following cell lines were used: BHK-21 (clone 13) (85011433), BHK-21 LacZ [32] and 9L 
lacZ (ATCC-CRL-2200) [33]. 
 
Construction and characterisation of viral vectors 
Production of the oncolytic vector OncoVEX is described by ref. 26. The cassettes 
expressing shRNA or artificial miRNA against lacZ or enhanced green fluorescent protein 
(eGFP) are described by ref. 32. They express shRNA and pre-miRNA sequences from the 
U6 polymerase III and CMV polymerase II promoters, respectively. The pR19 cassette is 
flanked by HSV-1 LAT sequences.  
 
B-galactosidase activity assay  
B-galactosidase enzyme activity was assessed using high sensitivity β-galactosidase assay 
kit (Stratagene). BHK-LacZ cells were plated at 1.5x105 cells per well of 24-well tray and 
incubated at 370C overnight. Cells were infected with Onc miR-LacZ, Onc miR-neg, Onc 
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U6shLacZ and Onc U6shGFP at multiplicity of infection (MOI) of 1, 0.1 and 0.01 and 
incubated at 370C for 24 hours. Cells were freeze-thawed in lysis buffer and spun at 
12,0000g for 5mins to remove cell debris. 20ul of each cell lysate was added to the wells of 
a 96 well micotiter ELISA dish (IWAKI ELISA). 130ul of chlorophenol red-β-D-
galactopyranoside substrate was added and the samples were incubated at 370C until the 
substrate colour changed from yellow to brown. The reactions were terminated by 80ul of 
stop solution. The plate was read using an OPSYS MR plate reader (DYNEX technologies) 
at OD 570-595. 
 
Western blot analysis 
B-galactosidase protein levels were assessed by standard Western blot techniques, 
performed on 20ug of protein per sample and using primary antibodies: β-galactosidase 
(Abcam; ab616), a-tubulin (Abcam; ab4074) and secondary antibody: goat polyclonal to 
rabbit IgG-H&L-HRP (Abcam). 
 
In vivo xenograft tumour models 
All experimental procedures were performed with the authority of the Home Office, following 
UK guidelines and in accordance with best animal practice. Rat 9L/LacZ cells were 
implanted (1x107 cells) subcutaneously in the right flank of BALB/c nude mice (Harlan 
laboratories). Tumours were allowed to develop for 15 days to an average diameter of 
approximately 0.4-0.6cm and then injected with 108 pfu (100µl) of either Onc miR-LacZ or 
Onc miR-neg, and further incubated for 72hrs. B-galactosidase protein levels were either 
assessed by standard Western blot techniques or high sensitivity β-galactosidase assay kit 
(Stratagene). 
 
MTS cell viability assay and viral growth curves 
BHK-LacZ cells, were seeded in 96-well plates at a density of 2.5x104 cells per well and 
incubated at 370C O/N. Cells were infected with Onc miR-LacZ, Onc U6shLacZ or Oncovex 
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backbone at a multiplicity of infection (MOI) of 1, 0.1 and 0.01, and incubated at 370C for 24, 
48 and 72 hours. At each time point the supernatants were removed (stored at -800C) and 
the viral titre was determined using a standard viral plaque assay. Cell viability was 
determined using the CellTiter 96 AQueous One Solution Cell Proliferation Assay reagent 3-
(4, 5-dimethylthiazol-2-yl) -5- (3-carboxymethoxyphenyl) -2- (4-sulfophenyl) -2H- tetrazolium) 
(MTS) according to the manufacturer’s instructions (Promega). Briefly, 20µL of MTS reagent 
were added to each well together with180ul 2% FCS, RMPI, followed by incubation at 37oC 
for 15min - 4 hours. Absorbance was measured at 495nm. Survival was calculated as a 
percentage of the measurements taken in untreated cells. 
 
Results 
 
Development of oncolytic HSV RNAi viruses 
The polymerase III U6 promoter has been most commonly used to express shRNA from 
plasmid and viral vector systems. However, shRNA can be efficiently expressed from the 
CMV polymerase II promoter when embedded into endogenous miRNA sequences and 
these artificial miRNAs have been shown to induce specific degradation of target mRNAs 
similar to transfected siRNAs [34-36]. The microRNA-like expression system used in this 
study is based on miR-155 and takes advantage of the flexibility and variety of polymerase II 
promoters, which unlike polymerase III promoters, can be inducible and tissue-specific [37]. 
A reporter gene encoding emerald GFP is co-expressed from this system and allows 
labelling of transduced cells to aid the monitoring of silencing efficiency. 
 
RNAi viruses based on the OncoVEX oncolytic HSV backbone [28-30] were constructed by 
inserting cassettes expressing shRNA or miRNA against the gfp or lacZ reporter genes into 
the latency associated transcript (LAT) region of the HSV genome (Figure 1a). Expression of 
shRNA and pre-miRNA was driven by the U6 polymerase III and CMV polymerase II 
promoters, respectively. These RNAi cassettes have been described previously and showed 
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highly effective and specific silencing of reporter and endogenous gene expression in 
neurons, when inserted into replication-defective HSV-1 vectors [32].  
 
Oncolytic HSV can mediate expression of shRNA  
To identify whether shRNA could be expressed from an oncolytic HSV, BHK cells were co-
infected with a non-replicating HSV vector expressing eGFP (HSV CMVeGFP) and either 
the oncolytic virus Onc U6shGFP expressing shRNA against GFP or Onc U6shLacZ 
expressing shRNA against β-galactosidase, at an MOI 1.0. BHK cells are highly susceptible 
to HSV infection and at 24hrs over 90% of cells are GFP positive. Furthermore, whilst the 
majority of cells are infected with replicating HSV (cells with rounded morphology), only very 
few dead cells were detected in the media and the cultures appeared healthy. At 24hrs post-
infection, cells infected with Onc U6shGFP showed a significant reduction in GFP 
expression levels compared to the negative control (Figure 1b). Onc U6shLacZ failed to 
reduce GFP expression indicating that the silencing observed is not mediated by a non-
specific effect caused by the oncolytic HSV backbone. We can therefore conclude that it is 
possible to express active shRNA from an oncolytic HSV virus.  
 
Evaluation of oncolytic HSV-mediated expression of shRNA and miRNA 
To optimise silencing from oncolytic HSV, we compared viruses expressing shRNA or 
artificial miRNA against β-galactosidase from the U6 (Onc U6shLacZ) and CMV (Onc miR-
LacZ) promoters, respectively. Onc U6shGFP and Onc miR-neg, which expresses a non-
target pre-miRNA sequence under the control of the CMV promoter, were used as negative 
controls. These viruses were tested on the BHK-LacZ cell line, which constituently 
expresses β-galactosidase and is highly susceptible to HSV infection [32].  
 
To investigate the properties of oncolytic HSV expressing shRNA or miRNA, we performed 
an MTS cell viability assay at 24, 48 and 72 hours on BHK-LacZ cells infected with the 
oncolytic backbone virus OncoVEX, Onc U6shLacZ or Onc miR-LacZ at MOIs 1.0, 0.1 and 
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0.01. Furthermore, we prepared growth curves for these viruses using the same time points. 
Figures 1g and 1h demonstrate that expression of shRNA/miRNA from the LAT region does 
not significantly influence the cytopathic effect and growth properties of oncolytic HSV, 
respectively. Figure 1g further demonstrates that cell death increases with time and MOI of 
virus.   
 
BHK-LacZ cells infected with Onc U6shLacZ, Onc miR-LacZ or each of the negative controls 
(Onc U6shGFP and Onc miR-neg) at an MOI of 1.0, 0.1 and 0.01 were assayed for β-
galactosidase expression at 24, 48 and 72 hours post-infection. At each MOI and time point 
tested, the number of cells and concentration of virus in each culture remain the same. 
Silencing of lacZ does not affect the cytopathic effect of the virus (Figure 1g) and thus, cell 
survival in cultures treated with controls, Onc U6shLacZ or Onc miR-LacZ is expected to be 
the same in each one of the conditions. To compare silencing between conditions with 
different levels of cell survival, β-galactosidase levels (% LacZ) were expressed as a 
percentage of the expression measured in the cells infected with the negative controls (Onc 
U6shGFP for Onc U6shLacZ, and Onc miR-neg for Onc miR-LacZ). Analysis of β-
galactosidase expression using enzyme activity assay revealed that both viruses which 
targeted lacZ significantly reduced β-galactosidase expression levels compared to the 
negative control viruses at most MOIs and timepoints tested, with the virus expressing 
artificial miRNA being consistently more effective than the virus expressing shRNA (Figure 
1c,d,e).  
 
At the earliest time point tested (24 hours), the most effective silencing occurred at the 
highest MOI of 1.0 (Onc U6shLacZ: 52.2% silencing; Onc miR-LacZ: 72.1% silencing, 
P=0.0012), whereas the least effective silencing was observed at the lowest MOI of 0.01 
(Onc U6shLacZ: 1.3% silencing; Onc miR-LacZ: 11.0% silencing, P=0.0033) (Figure 1c). At 
48 hours post-infection, both viruses resulted in increased β-galactosidase knockdown at all 
MOIs tested compared to the negative controls. However, the most effective silencing 
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occurred at the lower MOI of 0.1 (Onc U6shLacZ: 69.7% silencing; Onc miR-LacZ: 80.0% 
silencing, P=0.003) (Figure 1d). At 72 hours post-infection, silencing at the high MOIs was 
further reduced and the most effective silencing was observed with Onc miR-LacZ at an MOI 
of 0.01 (80.0% silencing) (Figure 1e). 
 
Figure 1f demonstrates β-galactosidase activity levels in cells infected with Onc U6shGFP 
and Onc miR-neg control viruses. All BHK-LacZ cells constituently express β-galactosidase 
and thus, β-gal activity levels are a good indication of the number of cells that have survived 
at each MOI and time point. As expected from figure 1g, β-galactosidase levels decrease 
with time and MOI of virus. At an MOI 1.0, silencing is optimal at 48hrs, when half of the cells 
in the culture remain healthy, and minimal at 72hrs, when the majority of cells are killed by 
the virus. At an MOI 0.01, however, optimal silencing is achieved at 72hrs, because the 
majority of cells in the culture remain healthy. Since β-galactosidase levels in BHK-LacZ 
cells infected with negative controls appear  to decrease with time and MOI of virus 
(Figure1f) as a result of cell death induced by the oncolytic backbone (Figure 1g) and neither 
the cytotoxicity nor the growth of oncolytic HSV are significantly affected by expression of 
RNAi triggers (Figure 1g and 1h), a significant further reduction in the levels of β-
galactosidase in cells infected with oncolytic HSV expressing either shLacZ or miR-LacZ 
(Figures c, d and e) can only be attributed to an RNAi-specific effect.   
 
Collectively, the above results indicate that in order to achieve optimal levels of silencing 
from a replicating HSV, it is important to balance the levels of shRNA/miRNA expression 
against cytotoxicity caused by the virus. Insertion of the same shRNA and miRNA 
expression cassettes in the LAT region of replication-defective HSV viruses resulted in 
expression of RNAi triggers in BHK-LacZ cells in the complete absence of viral replication 
[32]. Although expression of RNAi triggers from the LAT region is not dependant on viral 
replication, the initial number of cells infected and number of viral particles per cell (i.e. MOI) 
will determine the rate at which RNAi triggers are expressed. As viral genome copies 
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increase exponentially and cell growth rate decreases, even at very low MOIs, the virus will 
eventually infect all the cells in the culture and complete cytopathic effect (CPE) will be 
achieved. At high MOIs, high levels of RNAi triggers are expressed at early time points, but if 
the MOI is too high, the cells may not remain healthy long enough to allow the RNAi triggers 
to act. Conversely, at low MOIs, high levels of RNAi triggers will be expressed at later time 
points, but the cells remain healthier longer to allow the RNAi triggers to induce effective 
silencing. 
 
Finally, expression of miRNA from the CMV polymerase II promoter silenced target gene 
expression more efficiently than expression of shRNA from the U6 polymerase III promoter 
at every time point and MOI tested (unpaired student t tests). These results contrast with 
data in BHK-LacZ cells using non-replicating HSV expressing shRNA or miRNA from the 
same cassettes, which showed no significant difference between shRNA expressed from 
different promoters [32]. On the basis of these results Onc miR-LacZ was used for the in 
vitro and in vivo tumour cell studies described below.  
 
Oncolytic HSV-mediated silencing in glioma cells in culture 
Oncolytic HSV has been shown to infect a wide range of tumour cell types, including glioma 
[38-42], colon carcinoma [43], prostate cancer [44,45], non-small cell lung cancer [46], 
gallbladder carcinoma [47], head and neck squamous cell carcinoma [48], oesophageal 
adenocarcinoma [49], breast cancer [50], thyroid cancers [51], hepatocellular carcinoma [52] 
and neuroblastoma [53, 54], with variable efficiencies. The HSV genome, therefore, 
potentially offers a multifunctional platform from which to knockdown tumour-related 
transcripts, which could be used to help limit tumour immune suppression or tumour growth 
as a whole. 
 
The 9L/lacZ rat gliosarcoma cell line was developed from the parental 9L cell line by 
transduction with the BAG replication-deficient retroviral vector carrying the E. coli lacZ 
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gene. These cells constitutively express high levels of β-galactosidase from the 9L genome 
and are moderately susceptible to HSV infection [30]. Moderately susceptible tumour cells 
allow HSV entry and replication, but at a much lower rate than that required for effective 
tumour killing. As a result, a lower number of cells in a tumour will get infected by the virus at 
any given dose than in more susceptible cell types. While the virus will eventually kill 
infected cells, the process is slower. The lower level of viral replication will also result in a 
lower number of infectious particles being released to infect neighbouring tumour cells. 
When the kinetics of tumour cell killing do not exceed tumour growth, expression of shRNA 
or miRNA in combination to the viral cytopathic effect may be beneficial. Expression of RNAi 
triggers from the LAT region is not dependant on viral replication and will therefore result in 
the production of numerous silencing molecules from a single viral genome copy, which has 
the potential to improve the oncolytic properties of HSV by compensating for low viral 
particle numbers. Furthermore, the oncolytic process is slower, which may allow silencing 
molecules to accumulate and induce effective silencing of targeted genes before infected 
cells are killed by the virus. We have previously shown in vivo that OncoVEX replication 
inhibits the growth of 9L tumours in the flanks of nude F344 rats but fails to cure the tumours 
[30]. Similar results were obtained with this virus in RG2 glioma cells. Furthermore, 
expression of prodrug activation genes from this oncolytic backbone enhanced the 
cytopathic effect of the virus in 9L cells [30]. 9L cells are therefore an appropriate model in 
which to test oncolytic HSV-mediated silencing.  
 
To test whether expression of miRNA from oncolytic HSV could achieve silencing in tumour 
cells in culture, we infected the 9L/LacZ cells with Onc miR-LacZ or Onc miR-neg, at an MOI 
of 1.0, 5.0 and 10.0. Optimal silencing in BHK cells was achieved at 48hrs, MOI 0.1. 9L cells 
are moderately susceptible to HSV infection compared to BHK cells and thus, considerably 
higher MOIs were used. B-galactosidase activity assay at 48 hrs post-infection demonstrated 
62.5% silencing at MOI 1.0 (P=0.0007), 34.7% silencing at MOI 5.0 (P=0.0001) and no 
silencing at MOI 10.0 (Figure 2b). Figure 2b further demonstrates that 5 times more cells 
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were killed by the virus at MOI 5.0 compared to MOI 1.0, and 1.5 times more cells were 
killed at MOI 10.0 compared to MOI 5.0. To investigate the reason lacZ silencing achieved in 
these cells was moderate compared to silencing in BHK-LacZ cells, we assessed the levels 
of GFP expressed from miR viruses that enable direct labelling of infected cells. Fluorescent 
microscopy in 9L/LacZ infected with Onc miR-neg at 48hrs revealed that only a proportion of 
cells are infected at an MOI 1.0 (Figure 2a). At MOIs 5.0 and 10.0, nearly all cells in the 
cultures are killed by the virus (data not shown). Thus, that optimal silencing in 9L cells at 
48hrs can be achieved between MOI 1.0 and 5.0, i.e. at considerably higher doses than 
those needed to achieve near complete silencing in a highly susceptible cell line. 
 
The above data revealed that expression of miRNA from an oncolytic HSV virus can induce 
silencing in a tumour cell line. Although the 9L/LacZ rat glioma cell line is infected with 
relatively low efficiency and thus, lacZ is only partially silenced, this cell line is an appropriate 
model to study oncolytic HSV-mediated silencing, as silencing is expected to be particularly 
useful in tumours which are less efficiently infected by the virus and thus, not completely 
killed by oncolytic HSV treatment. 
 
Oncolytic HSV-mediated silencing in tumours in vivo 
To investigate oncolytic HSV-mediated silencing in tumours in vivo, we injected the flanks of 
nude mice with 9L/LacZ cells and allowed tumours to develop. The resulting tumours were 
injected with 108 pfu of either Onc miR-LacZ or Onc miR-neg and were analysed for β-
galactosidase expression by Western blot and enzyme activity assay 72 hrs post-injection. 
Quantitative RT-PCR revealed similar levels of GFP transcripts within tumours injected with 
either virus (data not shown). Western blot analysis of tumours isolated from animals 
injected with Onc miR-LacZ (n=4) demonstrated knockdown of β-galactosidase levels 
compared to tumours injected with Onc miR-neg (n=2) (Figure 2c). Moderate reduction in 
protein levels is difficult to convincingly demonstrate using western blot. Furthermore, β-
galactosidase is highly expressed in 9L tumour cells and has a very long half-life resulting in 
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high background, which makes quantification of western blots using band density very 
difficult. For these reasons, knockdown of β-galactosidase was confirmed using β-gal 
enzyme activity assay, which is quantitative and considerably more sensitive than western 
blot. B-galactosidase activity assay on the same tumours revealed that non-injected tumours 
expressed the highest levels of β-galactosidase (n=2), injection with Onc miR-neg resulted in 
an average 19.4% silencing of lacZ (n=2) compared to non-injected tumours (P=0.005), and 
injection with Onc miR-LacZ resulted in 49±5.9% silencing of lacZ (n=4) compared to 
tumours injected with the Onc miR-neg control (P=0.0001) (Figure 2d). We have previously 
shown that the oncolytic virus used in this study can inhibit the growth of 9L tumours in the 
flanks of F344 rats [30]. Therefore, we can conclude, that the 19.4% difference in the levels 
of β-galactosidase between non-injected tumours and tumours injected with miR-neg control 
is due to oncolysis caused by the viral backbone. 49% silencing in tumours in vivo is a highly 
promising result bearing in mind that 9L/LacZ cells are moderately susceptible to HSV 
infection. These results indicate that an oncolytic HSV expressing shRNA/miRNA has the 
potential to silence target gene expression in tumours in vivo, which had not been previously 
demonstrated.  
 
Discussion 
Unlike oncolytic adenoviral vectors, which replicate at a very slow rate and have been shown 
to induce RNAi in tumours [18-20], replicating HSV was not considered a suitable vector 
from which to express RNAi triggers, because it is robustly oncolytic. This study is the first to 
show oncolytic HSV-mediated expression of shRNA and artificial miRNA. Our results 
demonstrate effective and specific silencing of a reporter gene in tumour cells both in vitro 
and in vivo. We also demonstrate that expression of shRNA from an oncolytic HSV 
backbone can be driven from either a polymerase II or III promoter, although expression 
from the CMV promoter was comprehensibly more effective. The use of artificial miRNAs 
has become a very attractive alternative to the expression of shRNA. Artificial miRNAs are 
amenable to RNA polymerase II transcription and polycistronic strategies, which allow 
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delivery of multiple shRNA sequences simultaneously and co-expression of a biomarker or 
biologically active protein together with the shRNA.  
 
Furthermore, we show that oncolytic HSV-mediated silencing can be achieved in cell types 
that are either highly susceptible or moderately susceptible to HSV infection. We show that 
when oncolytic HSV is given at the right dose, shRNA can be expressed and effective 
silencing can be induced in an infected cell, before the cell is killed by the virus. Thus, 
delivery of RNAi to tumours using oncolytic HSV provides the potential to improve tumour 
cell killing by silencing tumour-related genes. For example, induction of RNAi in combination 
with the virus oncolytic effect may be able to improve response rates seen in human clinical 
trials with oncolytic viruses. Moreover, expression of shRNA from oncolytic HSV may be 
useful in enhancing cell killing in tumours that are relatively less susceptible to HSV 
infection. We show that expression of RNAi triggers from the LAT region, which is not 
dependant on viral replication, is sufficient to induce silencing of a target gene despite a low 
viral particle number in tumours where HSV infection and/or replication are moderate. When 
the shRNA or miRNA is engineered to target proteins secreted by tumour cells, which aid 
their growth or promote local immune suppression, moderate silencing in these tumours may 
be sufficient to promote cell death in both infected and non-infected cells in a tumour.  
 
As the process of lytic virus replication is effective at destroying injected tumours, the most 
appropriate targets for RNAi-mediated knockdown using this approach would be expected to 
be secreted tumour proteins involved in processes such as angiogenesis or local immune 
suppression. Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis. 
Up-regulation of VEGF is important in blood vessel formation in solid tumours [55] and 
mediates tumour evasion of immune surveillance by inhibiting the development of dendritic 
and other hematopoetic cells [56]. In recent years, numerous studies have demonstrated 
that silencing of VEGF by non-viral-mediated delivery of siRNA leads to reduction in tumour 
size of up to 90% [57, 58, 59, 60]. To improve delivery of RNAi triggers against VEGF, non-
 16
replicating viruses were generated [61, 62]. More recently, replication-competent 
adenoviruses expressing shRNA against VEGF and Interleukin-8 were shown to affect 
angiogenesis and inhibit tumour growth [19, 20]. Other factors secreted by tumours, such as 
Interleukin-10 (IL-10) and transforming growth factor-β (TGF-β), are attractive targets for 
knockdown using oncolytic HSV. IL-10 is an anti-inflammatory, immunosuppressive cytokine 
that is involved in tumour escape from immune surveillance [63]. Elevated IL-10 levels have 
been found in a variety of human malignant tumours and are an independent prognosis 
factor for decreased response to chemotherapy in patients with advanced gastrointestinal 
malignancies [64, 65]. In a malignant B-1 cell line derived from a murine model of chronic 
lymphocytic leukaemia, induction of RNAi against IL-10 resulted in anti-proliferative and pro-
apoptotic effects [66]. TGF-β is a multifunctional polypeptide which switches its role from a 
tumour suppressor in normal cells to a tumour promoter in advanced cancers. TGF-β 
protein-receptor interactions promote processes such as immune suppression, tissue 
remodelling and formation of blood vessels, which lead to the growth and metastasis of 
cancer cells [67]. TGF-β is the prototypic member of a large superfamily of secreted proteins 
that include three TGF-β isoforms (TGF-β1, TGF-β2 and TGF-β3). Antisense 
oligonucleotides against TGF-β1 developed for the treatment of non-small cell lung 
carcinoma, colorectal and prostate carcinomas have shown efficacy in preclinical 
development [68]. Antisense oligonucleotides against TGFβ2 have been tested in a number 
of clinical trials against various cancers, with promising results [69].   
 
Infection with wild-type HSV results in expression of virion host shutoff protein (vhs), which 
leads to mRNA degradation and shutdown of host cell protein synthesis. However, whilst a 
proportion of cellular mRNAs that mainly encode proteins involved in the cell immune 
response to virus infection are degraded, microarray analysis of gene expression has 
demonstrated that almost 500 genes are up-regulated more than 3-fold in HSV-1-infected 
cells, compared with mock-infected cells [70]. Moreover, whilst expression of GFP from a 
non-replicating HSV virus (Figure 1b) is not likely to be affected by vhs, due to viral mRNA 
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being transcribed at a higher rate than cellular mRNA, we demonstrate that lacZ, whose 
expression in 9L/LacZ cells resembles that of an endogenous gene, is not affected by vhs 
and can be specifically silenced both in vitro and in vivo (described in figure 2). Thus, 
although expression of vhs may alleviate the need to target certain cellular genes, 
expression of shRNA from an oncolytic HSV has the potential to allow specific silencing of 
genes that are not downregulated by HSV infection itself.  
 
Conclusion 
In summary, the current study provides the first demonstration that an oncolytic HSV can be 
used to induce RNAi to tumour cells in vitro and tumours in vivo. A combination of oncolytic 
HSV and RNAi technology offers the potential to further increase the effectiveness of 
oncolytic HSV therapy by inhibiting genes involved in tumour-related processes which may 
enhance the overall anti-tumour effect, especially in tumours that are only moderately 
susceptible to HSV replication. The vectors described in this study are being engineered to 
target a selection of tumour-related genes, and experiments are underway to investigate 
whether the effectiveness of oncolytic virus treatment can be improved in tumours 
moderately susceptible to HSV infection when these targets are silenced. 
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Figure 1. Construction and characterisation of oncolytic HSV viruses expressing 
shRNA. (a) Schematic representation of the oncolytic HSV genome and RNAi expression 
cassettes used in this study. Generation of OncoVEX viruses is described by Liu et al., 2003 
and generation of replication-defective HSV-1 vectors is described by Anesti et al., 2008. (b) 
BHK cells were dually infected with a non-replicating HSV CMVeGFP virus and either Onc 
U6shGFP or Onc U6shLacZ, at an MOI of 1.0, and incubated for 24hrs. The cells were 
digitally photographed using an UV-inverted microscope (Nikon Eclipse TE200) and Lucia 
Imaging (MV-1500 version 4.6). (c,d,e) BHK-LacZ cells 29 were infected at various MOIs (1, 
0.1, and 0.01) with oncolytic HSV viruses expressing shRNA (Onc U6shLacZ) or pre-miRNA 
(Onc miR-LacZ) against lacZ, or the negative control viruses Onc U6shGFP and Onc miR-
neg. Infected cells were harvested at 24, 48 and 72hrs and β-galactosidase protein levels 
were assessed by high sensitivity β-galactosidase assay (Stratagene). B-galactosidase 
levels (%LacZ) were expressed as a percentage of the expression measured in the cells 
infected with the negative controls (Onc U6shGFP for Onc U6shLacZ, and Onc miR-neg for 
Onc miR-Lac. (f) B-galactosidase activity (units/ml) in BHK-LacZ cells infected with Onc 
U6shGFP and Onc miR-neg control viruses at an MOI 1.0, and incubated for 24hrs, 48hrs 
and 73hrs, or at an MOI 1.0, 0.1 and 0.01, and incubated at 72hrs. BHK-LacZ cells 
constitutively express lacZ and thus, β-galactosidase levels are a good indication of cell 
survival. All P values were obtained using unpaired student t test. (g) BHK-LacZ cells were 
infected with OncoVEX, Onc U6shLacZ or Onc miR-LacZ at an MOI of 1.0, 0.1 and 0.01. 
MTS cell viability assay was performed at 24, 48 and 72 hours post-infection. Cell death 
increases with time and MOI of virus. Expression of shLacZ or miR-LacZ does not 
significantly affect cytotoxicity caused by the oncolytic virus. (h) BHK-LacZ cells were 
infected with OncoVEX, Onc U6shLacZ or Onc miR-LacZ. Growth curves were prepared by 
counting plaque forming units at 24, 48 and 72 hours post-infection. Expression of shLacZ or 
miR-LacZ does not significantly influence the growth of the oncolytic virus. 
 
 
 26
Figure 2. Silencing in glioma cells in vitro and in vivo. (a) Rat 9L/LacZ [30] cells were 
infected at an MOI of 1.0 with Onc miR-neg and incubated for 48hrs. GFP levels were 
assessed by fluorescent microscopy. (b) Rat 9L/LacZ cells were infected at an MOI of 1.0, 
5.0 and 10.0 with Onc miR-LacZ or Onc miR-neg, and incubated for 48hrs. B-galactosidase 
protein levels (units/ml) were assessed using high sensitivity β-galactosidase assay 
(Stratagene). P values were obtained using unpaired student t test. (c,d) Rat 9L/LacZ cells 
were implanted (1x107 cells) subcutaneously in the right flank of BALB/c nude mice (Harlan 
laboratories). Tumours were allowed to develop for 2 weeks to an average diameter of 
approximately 0.4-0.6cm and then injected with 108 pfu (100µl) of either Onc miR-LacZ or 
Onc miR-neg, and further incubated for 72hrs. B-galactosidase protein levels were either 
assessed by standard (c) Western blot techniques or (d) high sensitivity β-galactosidase 
assay kit (Stratagene). 
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